Market Overview

UPDATE: Morgan Stanley Reiterates On CIGNA As 4Q Issues May Linger

Related CI
Top 4 NYSE Stocks In The Health Care Plans Industry With The Highest Profit Margin
Humana Forms Another ACO - Analyst Blog

In a report published Friday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating on CIGNA (NYSE: CI), but lowered the price target from $100.00 to $93.00.

In the report, Morgan Stanley noted, “Issues CI experienced in 4Q may spill over into 2014 results. However, >$1.5B in deployable cash in FY14 and improvements in 2H14 should yield mid single-digit EPS growth. Our adjusted EPS of $7.16 reflects 6% Y/Y growth off a lower 2013 platform.”

CIGNA closed on Friday at $76.14.

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (CI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free